Tuberculosis

What is Tuberculosis?

Tuberculosis (TB) is a dreaded bacterial infection. It has been known to mankind since ancient ages. It was commonly called “consumption” at the turn of the last century because of the way the disease seemed to “consume” the individual it affected.

Tuberculosis Causes

Tuberculosis Diagnosis

Tuberculosis Prevention

Tuberculosis Screening

Tuberculosis Treatment

Tuberculosis Prognosis

History of Tuberculosis

Tuberculosis in Animals

Tuberculosis Transmission

New tuberculosis technologies: importance of access in the private health sector

Latest Tuberculosis News and Research

Artificial Intelligence brings a novel antibiotic compound

Researchers from the Massachusetts Institute of Technology (MIT) have made a scientific breakthrough where their machine-learning algorithm or Artificial Intelligence (AI) program successfully created a novel antibiotic compound. The drug has since then been tested on deadly bacteria in the lab, and in lab mice with a considerable amount of success, explain the researchers. The study results appear in the latest issue of the journal Cell.

20 Feb 2020

Purdue scientists receive $3.2 million NIH grant to target antimicrobial resistance

New support may help Purdue University scientists target what they call one of the greatest threats to human health - antimicrobial resistance.

20 Feb 2020

Antibiotic resistance poses a growing risk during pandemics

Researchers investigating the drug prescription response to a "superbug" enzyme that renders bacteria resistant to antibiotics are available to discuss why such resistance is posing a growing risk during pandemics such as the current coronavirus.

14 Feb 2020

Newly discovered antibiotics kill bacteria differently

Antibiotic resistance is a growing public health problem across the globe, with many diseases becoming harder to treat. Now, a newly discovered antibiotic group shows promise in the fight against superbugs as it has a unique way of killing bacteria.

13 Feb 2020

Coronavirus tests public health infrastructure in the heartland

Every weekday at noon since Jan. 27, the Missouri Department of Health and Senior Services Director Randall Williams gathers his outbreak response team for a meeting on coronavirus.

13 Feb 2020

Researchers engineer probiotics to safely deliver immunotherapies to tumors

Researchers at Columbia Engineering have engineered probiotics to safely deliver immunotherapies within tumors.

12 Feb 2020

Recent progress in TB diagnostics and prevention approaches offers hope for future

In September 2018, the National Institute of Allergy and Infectious Diseases, part of the NIH, issued its Strategic Plan for Tuberculosis Research, which outlined research priorities to reduce and ultimately end the burden of tuberculosis.

11 Feb 2020

Advanced X-ray combination technique aids tuberculosis and osteoporosis research

With an advanced X-ray combination technique, scientists have traced nanocarriers for tuberculosis drugs within cells with very high precision.

4 Feb 2020

UH professor examines life cycle of drug-resistant persister cells in recurrent infections

A University of Houston engineering professor is examining the life cycle of stubborn, drug-resistant persister cells in recurrent infections to find a way to destroy them.

4 Feb 2020

Advances in tuberculosis research yield immune responses

A new study published in January 2020 in the journal Science Translational Medicine depicts for the first time ever a beautifully detailed map of the way three different species reacts to tuberculosis, based on their genetic and immune differences.

30 Jan 2020

Study maps immune responses to tuberculosis across 3 species

Tuberculosis is one of the world's most vexing public health problems. About 1.5 million people died from this bacterial lung infection in 2018, and the World Health Organization estimates that one-quarter of the world's population -- some 2 billion people, mostly in developing countries -- are infected with the bacteria that causes TB.

30 Jan 2020

ERA4TB to transform the development of new therapies for tuberculosis

With a team of more than thirty public and private organisations and a budget over 200 million euro, ERA4TB aims to radically transform the way in which new therapies are developed for the treatment of tuberculosis.

30 Jan 2020

Global funding for neglected disease research reaches a record high

For the first time, global funding for neglected disease R&D grew for three consecutive years, reaching a record high of more than US$4.05 billion in 2018.

30 Jan 2020

BCG vaccine formulations vary widely in their characteristics, study shows

Each year, more than 100 million newborns around the world receive vaccinations against Mycobacterium tuberculosis, or TB, which infects about one-quarter of the world's population.

28 Jan 2020

The challenge of new antibiotic discovery

It is important to discover antibiotic drugs and to bring them to clinical use, a task made all the more urgent by the increase in the number of infections that are resistant to existing antibiotics. However, this task is a formidable one.

28 Jan 2020

Deadly infection in cystic fibrosis could be curbed with combination medication

Researchers from Aston University and Birmingham Children’s Hospital have developed a new medication regimen that could successfully treat a bacterial infection that could prove fatal to patients with cystic fibrosis or bronchiectasis. The results of the new study were published in the latest issue of the journal Scientific Reports.

27 Jan 2020

Indoor dust carrying bacteria that could be harbouring antibiotic resistance

Bacteria enter our homes on our the skin, or through the air, but once inside they may transfer antibiotic resistance traits to other bacteria residing in the indoor dust, a possibility raised by a new study

26 Jan 2020

New drug combination destroys bacterial infection that can be fatal to cystic fibrosis patients

A new treatment developed by researchers at Aston University and Birmingham Children's Hospital has been found to completely kill a bacterial infection that can be deadly to cystic fibrosis patients.

24 Jan 2020

A New Discovery about MAIT Cells Sheds Light on Early-Phase HIV Infection

Researchers at the Karolinska Institutet, Sweden, have made an important discovery about a poorly understood group of immune cells (mucosa-associated invariant T [MAIT]cells) that could improve understanding of what happens during the initial stages of HIV infection.

14 Jan 2020

Study delineates the dynamic MAIT cell response during acute HIV infection

In a new study published in Nature Communications, researchers at Karolinska Institutet show that MAIT cells (mucosa-associated invariant T cells), part of the human immune system, respond with dynamic activity and reprogramming of gene expression during the initial phase of HIV infection.

14 Jan 2020